So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
Investor's Business Daily on MSN
Kymera rockets, pulling Nurix higher. Does it have the next Dupixent?
Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in ...
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...
Paris: French multinational pharmaceutical giant, Sanofi, has announced the completion of its acquisition of Vicebio Ltd.This ...
In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.
Canaccord raised the firm’s price target on Regeneron (REGN) to $1,057 from $850 and keeps a Buy rating on the shares. The firm said they expect ...
Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:45 AM ESTCompany ParticipantsJane Pritchett Henderson ...
Morgan Stanley flagged upside risks if pipeline data impresses, Dupixent intellectual property proves more durable, or Eylea HD adoption accelerates. Downside risks include trial setbacks, competitive ...
Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback